Oct 22 (Reuters) - Medtech firm Staar Surgical's ( STAA )

biggest investor, Broadwood Partners, is planning to

call a shareholder meeting to remove several directors, it said

on Wednesday, amid tensions over a proposed takeover by Swiss

eyecare firm Alcon.

Investment firm Broadwood has 27.5% stake and has actively

opposed Alcon's acquisition, saying the offer did not reflect

Staar's recent financial improvements and that the board has

failed to fully assess alternative options.

"It is clear to us that the board no longer has the

confidence of shareholders, and that new directors are needed to

properly steward the Company and restore shareholder trust,"

Neal Bradsher, Broadwood founder and president, said.

The special shareholder meeting to remove certain directors

is scheduled for Thursday when investors would also vote on the

proposed deal.

Staar did not immediately respond to a request for comment.

At least two other investors, Yunqi Capital and Defender

Capital, which together own 6.5% stake, have also objected to

the proposal, bringing the opposition to nearly 34% of

outstanding shares.

Earlier this month, proxy advisory firm Institutional

Shareholder Services recommended Staar investors to reject the

offer, citing the biggest shareholder's opposition and "various

deficiencies, disconnects, and uncertainties" tied to the deal.

Alcon said in early August that the boards of both

companies had approved its offer of $28 per Staar share, valuing

the business at $1.5 billion.

Staar, which produces and markets implantable lenses for the

eye, has struggled with declining revenue and a collapse of

sales in China.

(Reporting by Mariam Sunny in Bengaluru; Editing by Arun

Koyyur)